| Literature DB >> 28697309 |
Alun Bermingham1, Edmund Price1, Christophe Marchand2, Adel Chergui2, Alena Naumova2, Emily L Whitson1, Lauren R H Krumpe3, Ekaterina I Goncharova4, Jason R Evans4, Tawnya C McKee1, Curtis J Henrich1,3, Yves Pommier2, Barry R O'Keefe1,5.
Abstract
Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme crucial for cleavage of the covalent topoisomerase 1-DNA complex, an intermediate in DNA repair. TDP1 plays a role in reversing inhibition of topoisomerase I by camptothecins, a series of potent and effective inhibitors used in the treatment of colorectal, ovarian, and small-cell lung cancers. It is hypothesized that inhibition of TDP1 activity may enhance camptothecin sensitivity in tumors. Here, we describe the design, development, and execution of a novel assay to identify inhibitors of TDP1 present in natural product extracts. The assay was designed to address issues with fluorescent "nuisance" molecules and to minimize the detection of false-positives caused by polyphenolic molecules known to nonspecifically inhibit enzyme activity. A total of 227,905 purified molecules, prefractionated extracts, and crude natural product extracts were screened. This yielded 534 initial positives (0.23%). Secondary prioritization reduced this number to 117 (0.05% final hit rate). Several novel inhibitors have been identified showing micromolar affinity for human TDP1, including halenaquinol sulfate, a pentacyclic hydroquinone from the sponge Xestospongia sp.Entities:
Keywords: cancer and cancer drugs; enzyme assays or enzyme kinetics; natural products screening; tyrosyl-DNA phosphodiesterase
Year: 2017 PMID: 28697309 PMCID: PMC7900901 DOI: 10.1177/2472555217717200
Source DB: PubMed Journal: SLAS Discov ISSN: 2472-5552 Impact factor: 3.341